A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)
- Authors
- Ji, Jun Ho; Yun, Tak; Kim, Sung-Bae; Kang, Jung Hun; Park, Ji Chan; Cho, In Sung; Sohn, Chang Hak; Heo, Dae Seog; Jang, Joung Soon; Shin, Sang Won; Hwang, Deok Won; Sun, Jong-Mu; Park, Keunchil; Ahn, Myung-Ju
- Issue Date
- Nov-2012
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Nasopharyngeal cancer; Cisplatin; Weekly docetaxel
- Citation
- EUROPEAN JOURNAL OF CANCER, v.48, no.17, pp.3198 - 3204
- Indexed
- SCIE
SCOPUS
- Journal Title
- EUROPEAN JOURNAL OF CANCER
- Volume
- 48
- Number
- 17
- Start Page
- 3198
- End Page
- 3204
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/107158
- DOI
- 10.1016/j.ejca.2012.06.009
- ISSN
- 0959-8049
- Abstract
- Background: The purpose of this phase II study was to determine the efficacy and toxicity of cisplatin and weekly docetaxel combination chemotherapy as a first-line treatment in patients with recurrent or metastatic nasopharyngeal cancer. Patients and Methods: Recurrent or metastatic nasopharyngeal cancer patients were enrolled and received a combination of weekly docetaxel (35 mg/m(2) on Day1 and Day8) and cisplatin (70 mg/m(2) D1) every 21 days, for up to a maximum of 6 cycles. The primary endpoint was objective response rate, and the secondary endpoints included toxicity of combination chemotherapy, progression-free survival, overall survival and 1-year survival rate. Results: In total, 47 patients were enrolled and analysed, and 46 patients (97.9%) completed the planned protocol. In an intent-to-treat analysis, 6 patients (12.8%) achieved complete response (CR) and 27 patients (57.4%) showed partial response (PR), with an objective response rate of 70.2%. The median progression-free survival and overall survival were 9.6 months (95% C.I. 5.7-13.5 months) and 28.5 months (95% C.I. 16.9-40.1 months), respectively, and the 1-year survival rate was 89.9%. The common grade 3 adverse events were stomatitis (1.2%), neutropenia (0.8%), anaemia (0.8%), infection (0.8%) and diarrhoea (0.8%). Grade 4 adverse events were not observed in this study. Conclusions: The combination chemotherapy of cisplatin and weekly docetaxel is highly effective and shows favourable toxicity as a first-line chemotherapy in patients with recurrent or metastatic nasopharyngeal cancer. (C) 2012 Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholar.korea.ac.kr/handle/2021.sw.korea/107158)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.